Irritable Bowel Syndrome
Pipeline by Development Stage
Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.
Key Trends
- AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
- Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
- Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds
Career Verdict
Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LINZESS (linaclotide) | AbbVie | $1.8B | 25% | Peak | Stable | 7.7yr |
| 2 | CREON (pancrelipase) | AbbVie | $1.5B | 21% | LOE Approaching | Declining | |
| 3 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 15% | LOE Approaching | Declining | |
| 4 | RINVOQ (upadacitinib) | AbbVie | $976M | 13% | Peak | Growing | 11.8yr |
| 5 | XELJANZ XR (tofacitinib) | Pfizer | $586M | 8% | Peak | Stable | 8.3yr |
Drug Class Breakdown
mature portfolio anchor
well-established class
facing biosimilar competition
growing IBD adoption
commoditized
Career Outlook
StableGastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.
Breaking In
Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.
For Experienced Professionals
Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.
By Department
Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.
Competitive Landscape
38 companies ranked by most advanced pipeline stage
+8 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (50)
Total enrollment: 7,682 patients across 50 trials
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome
SH-DS01 on Fecal Metagenomic Stability
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
Mesalazine Treatment in IBS (The MIBS Study)
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Diarrhea Predominant Irritable Bowel Syndrome in Females
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake
A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet
Endomicroscopic Evaluation of Food-induced Gastrointestinal Mucosal Alteration
Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue
Edible Insects: Good for the Gut and the Globe
The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome
Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.
Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome
The Efficacy of Sodium Butyrate and Probiotics in Patients With Irritable Bowel Syndrome
Percutaneous Electrical Nerve Field Stimulation for Adults With Irritable Bowel Syndrome
Brain-Gut-Microbiota Interaction in IBS
Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
SMART Program in Irritable Bowel Syndrome (IBS)
Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation
Mobile Self-Management of Irritable Bowel Syndrome for Adolescents
Phenotyping IBS: Perceptions and Modulations of Visceral Sensations
Related Jobs in Gastroenterology
Senior Manager, FP&A
Head of Drug Product Development
Senior Director, Investor Relations and Corporate Communications
Clinical Operations Lead, Development Operations
Director, Global Regulatory Affairs (GRA) - CMC
Senior Scientist, Computational Chemistry
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.